Compare Deckers Outdoor Corp (DECK) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Deckers Outdoor Corp vs Mesoblast Limited — how do they compare? Deckers Outdoor Corp trades at $107.17 (market cap $14.80B), while Mesoblast Limited trades at $18.15 (market cap $2.12B). The key difference: Deckers Outdoor Corp is far larger — about 7× Mesoblast Limited's market cap. Which is the better fit depends on your goals.
| DECK | MESO | |
|---|---|---|
Market Cap | $14.80B | $2.12B |
Sector | Consumer Cyclical | Technology |
52-Week High | $123.91 | $20.96 |
52-Week Low | $79.54 | $10.96 |
Enterprise Value | $13.27B | $2.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DECK trades at $107.80, up 1.71% for the day, with a bullish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.96 exceeding the $0.83 estimate. Revenue grew to $4.99B in 2025, and net income reached $966M. Analyst consensus price target is $122.44, suggesting potential upside. Recent news highlights robust brand momentum for UGG and HOKA, with international sales growth offsetting domestic stagnation.
Outlook remains positive driven by earnings growth and strong cash flow, but risks include reliance on key brands and competitive pressures. The stock offers a reasonable valuation with a P/E of 15.36 and high profitability metrics, though technical indicators show some overbought conditions near-term.
MESO trades at $16.22, up 5.05% today, with a bullish technical outlook from moving averages but mixed oscillators. The company shows strong gross margins of 80.52% but remains unprofitable with a net income margin of -144.33%. Recent news highlights commercial progress, including Ryoncil revenue of $36 million in Q4 2026 and pivotal Phase 3 trial milestones for chronic low back pain.
The outlook is cautiously optimistic, driven by FDA-approved Ryoncil's revenue growth and pipeline advancements, but high valuation (P/S 30.52) and persistent losses pose risks. Analyst consensus leans buy (45.46%), yet investors face volatility from clinical trial outcomes and cash burn concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Deckers Outdoor Corp
Deckers Outdoor Corp designs and sells casual and performance footwear, apparel, and accessories. Primary brands include UGG, Teva, and Sanuk. The company distributes Most of its products through its wholesale business, but it also has a substantial direct-to-consumer business with its company-owned retail stores and websites. Most sales are in the United States, although the company also has retail stores and distributors throughout Europe, Asia, Canada, and Latin America. Deckers sources its products from independent manufacturers primarily in Asia.
Read more on DECK →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
